Acipimox once daily in the treatment of primary hypertriglyceridemia

A. Branchi, D. Sommariva, A. Rovellini, L. Scapellato, M. Lavezzari, A. Fasoli

Research output: Contribution to journalArticle

Abstract

Sixteen patients with primary hypertriglyceridemia were treated, according to a double-blind crossover design, with acipimox 250 mg twice daily for one month and with acipimox 500 mg once daily for another month. The two treatments were separated by a one-month washout period. Serum triglycerides fell by 34% after both treatment periods. Apoprotein B decreased by 16% after acipimox 250 mg twice daily and by 24% after acipimox 500 mg once daily. Whole serum cholesterol significantly decreased only after acipimox 500 mg once daily and showed a trend toward a diminution after the other treatment period. High-density lipoprotein cholesterol and apoprotein A-I did not show significant changes. The comparison of the mean changes in serum lipids and apoprotein B during the two treatment periods failed to demonstrate significant differences. The lipid lowering activity of acipimox 500 mg a day was similar when the drug was taken in a single dose or in two divided doses.

Original languageEnglish
Pages (from-to)540-546
Number of pages7
JournalCurrent Therapeutic Research
Volume46
Issue number3
Publication statusPublished - 1989

Fingerprint

Hypertriglyceridemia
Apolipoproteins B
Therapeutics
Serum
Lipids
Apoproteins
Cross-Over Studies
HDL Cholesterol
acipimox
Triglycerides
Cholesterol
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Branchi, A., Sommariva, D., Rovellini, A., Scapellato, L., Lavezzari, M., & Fasoli, A. (1989). Acipimox once daily in the treatment of primary hypertriglyceridemia. Current Therapeutic Research, 46(3), 540-546.

Acipimox once daily in the treatment of primary hypertriglyceridemia. / Branchi, A.; Sommariva, D.; Rovellini, A.; Scapellato, L.; Lavezzari, M.; Fasoli, A.

In: Current Therapeutic Research, Vol. 46, No. 3, 1989, p. 540-546.

Research output: Contribution to journalArticle

Branchi, A, Sommariva, D, Rovellini, A, Scapellato, L, Lavezzari, M & Fasoli, A 1989, 'Acipimox once daily in the treatment of primary hypertriglyceridemia', Current Therapeutic Research, vol. 46, no. 3, pp. 540-546.
Branchi, A. ; Sommariva, D. ; Rovellini, A. ; Scapellato, L. ; Lavezzari, M. ; Fasoli, A. / Acipimox once daily in the treatment of primary hypertriglyceridemia. In: Current Therapeutic Research. 1989 ; Vol. 46, No. 3. pp. 540-546.
@article{bd3b9b2c73cb43c783349780b228111e,
title = "Acipimox once daily in the treatment of primary hypertriglyceridemia",
abstract = "Sixteen patients with primary hypertriglyceridemia were treated, according to a double-blind crossover design, with acipimox 250 mg twice daily for one month and with acipimox 500 mg once daily for another month. The two treatments were separated by a one-month washout period. Serum triglycerides fell by 34{\%} after both treatment periods. Apoprotein B decreased by 16{\%} after acipimox 250 mg twice daily and by 24{\%} after acipimox 500 mg once daily. Whole serum cholesterol significantly decreased only after acipimox 500 mg once daily and showed a trend toward a diminution after the other treatment period. High-density lipoprotein cholesterol and apoprotein A-I did not show significant changes. The comparison of the mean changes in serum lipids and apoprotein B during the two treatment periods failed to demonstrate significant differences. The lipid lowering activity of acipimox 500 mg a day was similar when the drug was taken in a single dose or in two divided doses.",
author = "A. Branchi and D. Sommariva and A. Rovellini and L. Scapellato and M. Lavezzari and A. Fasoli",
year = "1989",
language = "English",
volume = "46",
pages = "540--546",
journal = "Current Therapeutic Research - Clinical and Experimental",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "3",

}

TY - JOUR

T1 - Acipimox once daily in the treatment of primary hypertriglyceridemia

AU - Branchi, A.

AU - Sommariva, D.

AU - Rovellini, A.

AU - Scapellato, L.

AU - Lavezzari, M.

AU - Fasoli, A.

PY - 1989

Y1 - 1989

N2 - Sixteen patients with primary hypertriglyceridemia were treated, according to a double-blind crossover design, with acipimox 250 mg twice daily for one month and with acipimox 500 mg once daily for another month. The two treatments were separated by a one-month washout period. Serum triglycerides fell by 34% after both treatment periods. Apoprotein B decreased by 16% after acipimox 250 mg twice daily and by 24% after acipimox 500 mg once daily. Whole serum cholesterol significantly decreased only after acipimox 500 mg once daily and showed a trend toward a diminution after the other treatment period. High-density lipoprotein cholesterol and apoprotein A-I did not show significant changes. The comparison of the mean changes in serum lipids and apoprotein B during the two treatment periods failed to demonstrate significant differences. The lipid lowering activity of acipimox 500 mg a day was similar when the drug was taken in a single dose or in two divided doses.

AB - Sixteen patients with primary hypertriglyceridemia were treated, according to a double-blind crossover design, with acipimox 250 mg twice daily for one month and with acipimox 500 mg once daily for another month. The two treatments were separated by a one-month washout period. Serum triglycerides fell by 34% after both treatment periods. Apoprotein B decreased by 16% after acipimox 250 mg twice daily and by 24% after acipimox 500 mg once daily. Whole serum cholesterol significantly decreased only after acipimox 500 mg once daily and showed a trend toward a diminution after the other treatment period. High-density lipoprotein cholesterol and apoprotein A-I did not show significant changes. The comparison of the mean changes in serum lipids and apoprotein B during the two treatment periods failed to demonstrate significant differences. The lipid lowering activity of acipimox 500 mg a day was similar when the drug was taken in a single dose or in two divided doses.

UR - http://www.scopus.com/inward/record.url?scp=0024442857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024442857&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0024442857

VL - 46

SP - 540

EP - 546

JO - Current Therapeutic Research - Clinical and Experimental

JF - Current Therapeutic Research - Clinical and Experimental

SN - 0011-393X

IS - 3

ER -